Amgen warns investors of ‘mini-tender’ offer
Biotech giant Amgen warned investors of a so-called “mini-tender” offer by TRC Capital Corp. that seeks to buy half a million of the company’s shares at below-market prices ahead of its third quarter earnings. The unsolicited offer is dated Oct. 11 and offers to purchase up to 500,000 of Amgen common stock at $192 per Read More →
Read More →
Amgen CFO retiring in 2020
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen declares fourth-quarter dividend
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen gets go-ahead on two drugs
Regulators handed Amgen two victories for its drug portfolio, granting the Thousand Oaks biotech giant approval to treat a wider range of patients with osteoporosis and blood disorders. The U.S. Food and Drug Administration approved the use of Amgen’s immune thrombocytopenia drug Nplate for earlier use in adults Oct. 18, allowing it to be given Read More →
Read More →Westlake Village BioPartners leads $85 million investment to fight cancer
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Tri-county biotech upstarts struggle to maintain stock prices
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen trades cash for cash flow with Otezla deal
Amgen’s $13.4 billion acquisition of lucrative psoriasis therapy Otezla secures nearly a decade of revenue growth for the biotech giant to bridge the gap between its waning legacy products and potential new contenders. The relatively small deal could nonetheless change the landscape of the biotech industry, allowing regulators to approve a $74 billion takeover bid Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
